175,581 Shares of Fulgent Genetics, Inc. $FLGT Bought by Bank of America Corp DE
Bank of America Corp DE recently acquired 175,581 shares of Fulgent Genetics (NASDAQ:FLGT) valued at approximately $3.6 million, representing 0.64% of the company's stock. Despite this institutional investment, Fulgent Genetics reported weaker-than-expected quarterly results and currently holds a consensus "Hold" rating from Wall Street analysts with an average price target of $27.50. Corporate insiders have also been selling shares, further influencing the stock's performance.
Fulgent Genetics (FLGT) Short Interest & Short Float | Updated Sep 2026
This article provides an updated overview of Fulgent Genetics (FLGT) short interest and short float as of September 15, 2026. The company had 2.32 million shares sold short, representing 13.20% of its public float, marking a 2.12% decrease from the previous report. The short interest ratio stands at 6.7 days to cover, indicating moderate short seller sentiment.
PRPO vs. FLGT: Which Cancer Diagnostics Stock Has More Upside Now?
This article compares two cancer diagnostics companies, Precipio, Inc. (PRPO) and Fulgent Genetics, Inc. (FLGT), to determine which offers more upside potential for investors. While PRPO focuses on hematologic cancers and is expanding its product sales, FLGT provides a broader range of genetic testing services, integrated acquisitions, AI capabilities, and a therapeutic development business. The analysis concludes that FLGT appears to have more upside due to its diversified platform, strategic acquisitions, and more reasonable valuation compared to PRPO.
PRPO vs. FLGT: Which Cancer Diagnostics Stock Has More Upside Now?
This article compares two cancer diagnostics companies, Precipio, Inc. (PRPO) and Fulgent Genetics, Inc. (FLGT), to determine which stock offers more upside. While PRPO has strong growth drivers and improving cash generation, FLGT is recommended due to its more diversified platform, acquisition-driven expansion, AI capabilities, therapeutic pipeline, and a more favorable valuation compared to its historical levels.
Fulgent Genetics, Inc. $FLGT Shares Sold by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC
UBS Asset Management significantly reduced its stake in Fulgent Genetics (NASDAQ:FLGT) by 55.6% in the second quarter, selling 56,283 shares and retaining 45,020 shares valued at approximately $924,000. Institutional investors now own 48.06% of the company. Additionally, Fulgent Genetics insiders, including Hanlin Gao and Jian Xie, sold 5,932 shares worth $117,156, primarily to cover tax obligations from vested equity awards. The company also reported missing consensus estimates for quarterly EPS and revenue, and analysts currently maintain a "Hold" rating with an average price target of $27.50.
Public Employees Retirement System of Ohio Makes New Investment in Fulgent Genetics, Inc. $FLGT
The Public Employees Retirement System of Ohio has acquired a new stake of 55,247 shares in Fulgent Genetics, Inc. valued at approximately $1.13 million. This investment comes as institutional ownership in the company reaches 48.06%, despite Fulgent Genetics reporting weaker-than-expected quarterly results and maintaining negative profitability. Analyst sentiment is mixed, with a "Hold" rating, and two insiders recently sold shares to cover tax obligations.
Fulgent Genetics (NASDAQ: FLGT) officer to sell 45,304 vested shares for taxes
An officer at Fulgent Genetics (FLGT), Jian Xie, has filed a Rule 144 notice to sell 45,304 vested restricted shares. These shares, which vested on February 25, 2025, are being sold primarily to cover tax withholding obligations through "sell to cover" arrangements, rather than being a discretionary trade. The filing also reports two previous sales by Xie in June and August 2026 for similar tax purposes.
Fulgent Genetics president and COO Xie Jian sells $41,809 in stock By Investing.com
Fulgent Genetics President and COO Xie Jian sold 2,127 shares of the company's common stock for a total of $41,809 to cover tax withholding obligations from vested restricted stock units. Following this transaction, Mr. Jian still directly owns 359,924 shares, with additional shares held indirectly. The sale comes as FLGT stock has gained 40% in six months but is down 25% year-to-date and is considered undervalued by InvestingPro.
Fulgent Genetics CSO Hanlin Gao sells $32,885 in stock By Investing.com
Hanlin Gao, Chief Scientific Officer at Fulgent Genetics (NASDAQ:FLGT), sold 1,673 shares of the company's common stock for $32,885 on September 2, 2026. This sale was primarily to cover tax obligations from vested restricted stock units. Despite this, Gao still beneficially owns 986,117 shares, and InvestingPro analysis suggests Fulgent Genetics is currently undervalued with more cash than debt.
Fulgent Genetics (NASDAQ:FLGT) COO Sells 2,127 Shares
Fulgent Genetics' COO, Jian Xie, sold 2,127 shares of the company's stock for approximately $41,816.82, primarily to cover tax obligations on vested equity awards. This sale decreased his holdings to 359,924 shares. The company's stock experienced a 1.9% dip, and its latest quarterly results missed analyst expectations with an adjusted EPS loss of $0.58 and revenue of $85.39 million.
Fulgent Genetics president and COO Xie Jian sells $41,809 in stock
Xie Jian, President and COO of Fulgent Genetics (NASDAQ:FLGT), sold 2,127 shares of company stock for $41,809 to cover tax withholding obligations from vested restricted stock units. Following the sale, Jian directly owns 359,924 shares and indirectly holds 220,816 shares through a family trust. This transaction comes after the company reported second-quarter financial results that missed Wall Street expectations, citing billing system issues and a reduced full-year outlook.
Fulgent Genetics (NASDAQ:FLGT) Insider Sells $32,891.18 in Stock
Hanlin Gao, an insider at Fulgent Genetics (NASDAQ:FLGT), sold 1,673 shares worth $32,891.18 to cover tax withholdings on vested equity awards, reducing his stake by 0.17%. This sale follows another recent transaction of 939 shares. The company recently reported a quarterly loss of $0.58 per share, missing consensus estimates, and revenue of $85.39 million, also below expectations, leading to a consensus "Hold" rating from analysts with an average price target of $27.50.
Fulgent Genetics CSO Hanlin Gao sells $32,885 in stock
Hanlin Gao, CSO of Fulgent Genetics (NASDAQ:FLGT), sold 1,673 shares of company stock for $32,885 on September 2, 2026, to cover tax withholding obligations from vested restricted stock units. Following this transaction, Mr. Gao beneficially owns 986,117 shares. This sale comes as the stock has gained 40% in six months, despite the company reporting an adjusted Q2 loss and revenue below expectations, leading to a lowered full-year outlook.
Fulgent Genetics (FLGT) officer plans stock sale to cover taxes
Fulgent Genetics officer Hanlin Gao has filed a Rule 144 notice to sell 1,673 shares of common stock on September 2, 2026, to cover tax withholding obligations related to previously vested restricted stock. This planned sale, valued at $32,885.20, is part of "sell-to-cover" transactions and not discretionary trading. Gao also reported similar tax-related sales of 1,688 shares on June 2, 2026, and 939 shares on August 27, 2026.
Jian Xie Sells 1,193 Shares of Fulgent Genetics (NASDAQ:FLGT) Stock
Jian Xie, COO of Fulgent Genetics (NASDAQ:FLGT), sold 1,193 shares of the company's stock for $23,752.63 to cover tax obligations. This sale reduced his holdings to 362,051 shares. The company recently reported weaker-than-expected quarterly results and currently holds a "Hold" rating from analysts with a consensus price target of $27.50.
Fulgent Genetics (NASDAQ:FLGT) Upgraded at Wall Street Zen
Wall Street Zen upgraded Fulgent Genetics (NASDAQ:FLGT) from a "strong sell" to a "sell" rating, although the overall analyst consensus remains "Hold" with a target price of $27.50. The company recently reported an adjusted loss of $0.58 per share and missed revenue estimates for the latest quarter. Despite this, institutional investors own 48.06% of the company, and insiders recently sold shares primarily to cover tax obligations.
Medina Value Partners LLC Buys New Stake in Fulgent Genetics, Inc. $FLGT
Medina Value Partners LLC has acquired a new stake in Fulgent Genetics, Inc. (NASDAQ:FLGT), purchasing 193,061 shares valued at approximately $3.96 million. This makes Fulgent Genetics the 27th biggest position in Medina Value Partners LLC's investment portfolio. Other institutional investors like Amundi, Goldman Sachs Group Inc., Legal & General Group Plc, Rhumbline Advisers, and American Century Companies Inc. also adjusted their holdings in the company.
Almitas Capital LLC Purchases New Holdings in Fulgent Genetics, Inc. $FLGT
Almitas Capital LLC has acquired a new position in Fulgent Genetics, Inc. (NASDAQ:FLGT), purchasing 104,797 shares valued at approximately $2.15 million. This acquisition makes Almitas Capital LLC an approximate 0.38% owner of the company, with institutional investors collectively holding 48.06% of the stock. The company recently reported weaker-than-expected quarterly results, and analysts maintain a cautious outlook with an average "Hold" rating and a target price of $27.50.
FLGT | Fulgent Genetics, Inc. Common Financials - Revenue Breakdown
This page provides a detailed financial overview of Fulgent Genetics, Inc. (FLGT), focusing on its revenue breakdown, alongside other financial data like insider trading, institutional holdings, lobbying activities, and patent grants. It also includes analyst ratings, stock forecasts, and a company profile, while indicating that specific revenue segment data is currently unavailable.
Renaissance Technologies LLC Decreases Stock Position in Fulgent Genetics, Inc. $FLGT
Renaissance Technologies LLC significantly reduced its stake in Fulgent Genetics, Inc. by 78.3% in Q1 2026, selling 64,864 shares and retaining 18,000 shares valued at $286,000. This divestment follows Fulgent Genetics' weaker-than-expected quarterly results, including an adjusted loss of $0.58 per share and revenue below analyst estimates. Analyst sentiment remains cautious, with an average "Hold" rating and recent downgrades.
Fulgent Genetics (NASDAQ:FLGT) Share Price Crosses Below Fifty Day Moving Average - Here's What Happened
Fulgent Genetics (NASDAQ:FLGT) saw its share price drop below its 50-day moving average, trading as low as $18.96 before closing at $19.74. The company missed its quarterly earnings expectations, reporting an adjusted loss of $0.58 per share against an estimated loss of $0.46, and revenue of $85.39 million compared to a $94 million consensus. Analyst sentiment remains mixed with a consensus "Hold" rating and a price target of $27.50.
Fulgent Genetics, Inc. $FLGT Shares Purchased by Quantinno Capital Management LP
Quantinno Capital Management LP significantly increased its stake in Fulgent Genetics, Inc. (NASDAQ:FLGT) by 374.7% in the first quarter, bringing its total holdings to 137,479 shares valued at $2.19 million. Institutional investors now own 48.06% of FLGT, while company insiders hold 36.18%, with recent insider sales primarily for tax obligations. Despite the increased institutional investment, analysts maintain a consensus "Hold" rating with a $27.50 price target, following the company's miss on quarterly revenue and EPS estimates and ongoing negative profitability.
Discipline and Rules-Based Execution in FLGT Response
This article analyzes Fulgent Genetics Inc. (NASDAQ: FLGT), highlighting a near-term strong sentiment despite persistent mid and long-term weakness. It identifies a mid-channel oscillation pattern and an exceptional 98.2:1 risk-reward setup, targeting a 28.2% gain versus 0.3% risk. The article details three AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis for various time horizons.
Fulgent Genetics, Inc. $FLGT Shares Sold by Dimensional Fund Advisors LP
Dimensional Fund Advisors LP significantly reduced its stake in Fulgent Genetics (NASDAQ:FLGT) by 24.4% in the first quarter, selling over 217,000 shares. This comes as Fulgent Genetics reported a quarterly loss and revenue below analyst expectations, contributing to a "Hold" consensus rating among analysts. Despite some institutional investors increasing their holdings, corporate insiders also sold shares, primarily to cover tax obligations.
Fulgent Genetics (FLGT) Q2 2026 Earnings Call Transcript
Fulgent Genetics (FLGT) reported Q2 2026 revenue of $85.4 million, up 4% year-over-year, but revised its full-year revenue guidance downward to $330-$340 million due to lower collection rates from a complex billing system transition. The company also reported an adjusted EBITDA loss of $17.1 million. Despite these challenges, Fulgent Genetics is advancing its therapeutic pipeline, with its lead oncology candidate FID-007 moving towards a Phase III trial, and is expanding its anatomic pathology services through recent acquisitions and AI integration.
Wall Street Zen Downgrades Fulgent Genetics (NASDAQ:FLGT) to Strong Sell
Wall Street Zen has downgraded Fulgent Genetics (NASDAQ:FLGT) from a "sell" to a "strong sell" rating, despite a broader analyst consensus of "hold" with a $27.50 price target. This downgrade follows Fulgent's recent quarterly earnings report, which missed analyst expectations for both EPS and revenue. Insiders have sold a significant number of shares, though some institutional investors have increased their holdings.
Price to sales forward of Fulgent Genetics, Inc. – MUN:7F0
This page from TradingView provides financial information for Fulgent Genetics, Inc. (MUN:7F0), specifically focusing on its forward price-to-sales ratio. The content appears to be a stub or a placeholder, as no specific values or detailed data regarding the price-to-sales metric are visible.
Fulgent Genetics, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:FLGT) 2026-08-07
This article presents the slide deck published by Fulgent Genetics, Inc. in conjunction with their Q2 2026 earnings call. The content is provided by Seeking Alpha's transcripts team, which publishes numerous quarterly earnings calls. The aim is to share transcript-related developments with readers.
Fulgent Genetics, Inc. (FLGT) Stock Price, News, Quote & History
This article provides a comprehensive overview of Fulgent Genetics, Inc. (FLGT), including its stock price, historical data, company profile, and financial performance. As of August 7, the stock closed at $19.14, up 3.18%. The company specializes in clinical diagnostic and therapeutic development solutions, offering a range of genetic and oncology tests, and is headquartered in El Monte, California.
Fulgent Genetics, Inc. (FLGT) stock price, news, quote and history
This article provides a detailed overview of Fulgent Genetics, Inc. (FLGT), including its current stock price, recent performance metrics, and key financial data. It also outlines the company's diagnostic and therapeutic solutions, target markets, and analyst ratings, alongside comparisons with similar companies in the healthcare sector.
FULGENT GENETICS INC : PIPER SANDLER RAISES TARGET PRICE TO $19.00 FROM $15.00
Piper Sandler has increased its target price for FULGENT GENETICS INC (FLGT.O) to $19.00, up from the previous $15.00. This adjustment reflects an updated outlook from the analyst firm regarding the company's valuation. The article briefly reports this change in target price.
FULGENT GENETICS INC : PIPER SANDLER RAISES TARGET PRICE TO $19.00 FROM $15.00
Piper Sandler has increased its target price for Fulgent Genetics Inc (FLGT.O) from $15.00 to $19.00. This update was reported by Reuters on August 4, 2026. The article itself is a brief announcement of this change.
FULGENT GENETICS INC : PIPER SANDLER RAISES TARGET PRICE TO $19.00 FROM $15.00
Piper Sandler has raised its target price for Fulgent Genetics Inc (FLGT.O) shares to $19.00 from $15.00. This update indicates a more optimistic outlook from the analyst firm regarding the company's future stock performance. The report was issued by Reuters on August 4, 2026.
Fulgent Genetics Inc (7F0) Q1 2024 Earnings Report - Results, Call & Slides
Fulgent Genetics Inc (7F0) has released its Q1 2024 earnings report, showing an actual EPS of -€0.01, beating the consensus EPS of -€0.28. The company's revenue for the quarter was €55.93M, missing the expected €56.69M, and showing a YoY revenue growth decline of 2.54%. The report includes details on the earnings call and slide deck, and provides a history of past earnings reports and future estimates.
Fulgent Genetics, Inc. (NASDAQ:FLGT) Receives Consensus Recommendation of "Hold" from Analysts
Analysts have issued a "Hold" consensus recommendation for Fulgent Genetics (NASDAQ:FLGT), with an average 12-month price target of $27.00. The company recently reported Q2 2026 revenue of $85.4 million, missing estimates, and a non-GAAP loss of $0.58 per share, which exceeded expectations. Management also lowered its full-year 2026 guidance, citing continued profitability and cash generation pressures.
Fulgent Genetics (NASDAQ:FLGT) Announces Quarterly Earnings Results
Fulgent Genetics (NASDAQ:FLGT) reported disappointing quarterly earnings, missing analyst estimates for both EPS and revenue due to revenue-cycle issues, including delayed billing and lower collection rates. The company also reduced its full-year 2026 guidance, forecasting lower revenue and negative non-GAAP EPS. Despite these setbacks, acquisitions and progress in its therapeutic pipeline offer potential offsets for future growth.
Fulgent Genetics (FLGT) Stock Price Slides As Losses Deepen Guidance Falls
Fulgent Genetics (FLGT) saw its stock price fall by approximately 18% after reporting a significant quarterly net loss of US$29.5 million and lowering its full-year guidance. The company's revenue increased slightly year-on-year, but profitability challenges persist, with widening losses and reduced non-GAAP gross margins. Analysts are now concerned about the company's persistent operating losses and cash burn.
Fulgent Genetics Inc reports results for the quarter ended June 30 - Earnings Summary
Fulgent Genetics Inc (FLGT) has released its earnings summary for the quarter ended June 30. The report, provided by Refinitiv, gives an overview of the company's financial performance. Full access to the article is available through a TradingView subscription.
Fulgent Genetics cuts FY26 revenue guidance amid billing delays
Fulgent Genetics reported Q2 2026 revenue of $85.4 million and a non-GAAP loss of $16.2 million, missing analyst estimates. The company lowered its full-year 2026 revenue guidance to $330-$340 million and non-GAAP loss to $63-$67 million, attributing the revisions to delays in its billing system transition. Despite strong cash reserves of $551.5 million and ongoing share repurchases, the revised outlook reflects significant margin compression and operational challenges.
Fulgent Genetics Q2 Earnings Call Highlights
Fulgent Genetics reported second-quarter 2026 revenue of $85.4 million, a 20% sequential increase, but faced challenges from billing system transition issues that pressured collections and gross margins, leading to a $29.5 million GAAP net loss. The company lowered its 2026 revenue guidance to $330 million-$340 million, citing weaker collection rates, slower new business growth, and a major customer bringing testing in-house. Despite these setbacks, Fulgent continues to advance integration efforts for acquisitions, develop an AI pathology tool, and progress its FID-007 and FID-022 drug candidates.
Fulgent Genetics (NASDAQ:FLGT) Updates FY 2026 Earnings Guidance
Fulgent Genetics (NASDAQ:FLGT) has updated its FY 2026 earnings guidance, projecting an EPS of -$2.35 to -$2.22 and revenue of $330 million to $340 million, which falls below consensus estimates. The company also missed Q2 earnings expectations, reporting an adjusted EPS of -$0.58 and revenue of $85.39 million. Analyst sentiment remains cautious, with a consensus "Hold" rating and a $27 average price target, while the stock recently traded at $20.21.
Fulgent Genetics Inc (FLGT) Financial Health: Profitability & Balance Sheet Analysis
Fulgent Genetics Inc (FLGT) currently holds a financial score of 6.89, placing it 52nd out of 75 in the Healthcare Providers & Services industry, indicating stable financial health and high operating efficiency. Despite this, its latest quarterly revenue decreased by 3.16% year-over-year to $71.14M, and its net profit saw a significant year-over-year decrease of 115.32%. The article also notes that relevant financial data regarding cash, assets, liabilities, and free cash flow have not yet been disclosed by the company.
Behavioral Patterns of FLGT and Institutional Flows
This article analyzes behavioral patterns and institutional flows for Fulgent Genetics Inc. (NASDAQ: FLGT), suggesting a near-term neutral sentiment that may pause mid- and long-term weakness. It highlights an exceptional 96.0:1 risk-reward setup targeting a 26.9% gain with minimal risk. The report also provides AI-generated trading strategies with specific entry, target, and stop-loss zones for different risk profiles and holding periods, based on multi-timeframe signal analysis.
FLGT|Fulgent Genetics Inc|Price:19.941|Chg%:+0.301
This article provides a comprehensive stock analysis of Fulgent Genetics Inc (FLGT) by TradingKey. It highlights the company's relatively healthy fundamentals, significant growth potential, and fair valuation, positioning it 46th in the Healthcare Providers & Services industry. The analysis also notes high institutional ownership, a "Hold" rating from analysts with a target price of $15.00, and a sideways trading pattern suitable for range-bound swing trading despite strong fundamentals.
Fulgent Genetics Inc (FLGT) Risk Assessment: Volatility, Financial Risk & Investment Risk
This article provides a risk assessment for Fulgent Genetics Inc (FLGT), noting its score of 6.80, which ranks 25 out of 75 in the Healthcare Providers & Services industry. The company's beta of 0.93 indicates it tends to underperform in up markets but decline less in down markets. Key metrics like volatility, maximum drawdown, and Sharpe ratio are presented across various timeframes.
Fulgent Genetics Inc expected to post a loss of 46 cents a share - Earnings Preview
Fulgent Genetics Inc (FLGT) is projected to report a loss of 46 cents per share in its upcoming earnings announcement. This preview indicates the anticipated financial performance for the company, suggesting a negative earnings per share.
Fulgent Genetics CSO Gao Hanlin Executes Tax-Related Sale of 1,645 Shares at $19.67 on July 26, 2026
Gao Hanlin, Chief Scientific Officer of Fulgent Genetics, Inc. (NASDAQ: FLGT), sold 1,645 common shares at $19.67 each on July 26, 2026, to cover tax obligations. Following this transaction, Hanlin still directly owns 988,729 common shares in the genomics testing company. The sale was disclosed in a regulatory filing with the SEC.
Fulgent Genetics Inc (FLGT) Cash Flow
This article provides a detailed quarterly and annual cash flow statement for Fulgent Genetics Inc (FLGT), covering operating, investing, and financing activities. It presents financial data including net income, capital expenditures, and changes in working capital over several years. The report also includes FAQs explaining different types of cash flow and how to interpret them for FLGT.
Fulgent Genetics Inc (FLGT) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides an overview of Fulgent Genetics Inc (FLGT) stock, focusing on its dividend and stock split history. It notes that the company has not distributed any dividends over the past five years. The page displays various financial metrics and stock performance data for FLGT.
Fulgent Genetics Inc (FLGT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a detailed revenue breakdown for Fulgent Genetics Inc (FLGT), categorized by business segments and regional contributions. For specific financial periods, it indicates the revenue proportions from Institutional, Insurance, and Patient segments, as well as from the United States and Foreign regions. The data highlights Institutional revenue and U.S. revenue as dominant contributors.
